Carcinoma Hcc Articles & Analysis
22 news found
Antengene also highlighted data from the 45 milligram (mg) per day monotherapy dosing cohort of the open-label Phase II TORCH Trial in subjects with Hepatitis B positive (HBV+) unresectable HCC who have received at least one prior line of systemic therapy (NCT03591965). ...
Additionally, ABK continues to significantly advance the development program of our Eye90 microspheres® radio-embolic technology that’s being investigated for the treatment of patients with unresectable Hepatic Cellular Carcinoma (HCC). Easi-Vue embolic microspheres share core technologies and design characteristics with Eye90 microspheres. ...
This study focused on the performance of Seravue and the LC-SPIK biomarker in detecting hepatocellular carcinoma (HCC) in a pool of nonalcoholic fatty liver disease (NAFLD) related cirrhosis patients. Here, LC-SPIK had an AUC of 0.841 and significantly outperformed AFP, the most common biomarker used for HCC detection today. Additionally, LC-SPIK ...
Senti Bio’s oncology pipeline is primarily focused on three preclinical-stage programs: SENTI-202, a Logic Gated (OR+NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML) cells while sparing the healthy bone marrow; SENTI-301, a regulatable Multi-Armed off-the-shelf CAR-NK cell therapy designed for the treatment of hepatocellular ...
“Senti Bio’s use of Logic Gated gene circuits in its off-the-shelf CAR-NK designs has the potential to selectively target tumors while sparing healthy cells and, I believe, expand the cell therapy opportunity to additional tumor types including acute myeloid leukemia, hepatocellular carcinoma, colorectal cancer and others. I am also drawn to the broad potential of the ...
“This year's ASGCT presentations mark significant progress across our pipeline of allogeneic gene circuit-enabled CAR-NK cell product candidates, particularly for our two lead programs in acute myeloid leukemia and hepatocellular carcinoma,” said Tim Lu, MD, PhD, Chief Executive Officer and Co-Founder of Senti Bio. ...
The prospective, single-center, open-label study is evaluating the safety and effectiveness of Eye90 microspheres in patients with unresectable hepatocellular carcinoma (HCC) or metastatic colorectal cancer (mCRC). Patients will receive a single Eye90 microspheres radioembolization treatment with follow-up visits for one year to assess safety, effectiveness, and ...
Senti Bio’s gene circuit technology is being applied in the design of multiple product candidates including SENTI-202 for the potential treatment of acute myeloid leukemia (AML), SENTI-301 for the potential treatment of hepatocellular carcinoma (HCC) and SENTI-401 for the potential treatment of colorectal cancer (CRC). ...
” Ten embolizations were performed in 8 patients with a range of tumor types, including hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), and angiomyolipoma (AML). ...
This technology is being applied in the design of multiple Senti Bio pipeline products including SENTI-301 and SENTI-401, which are aimed to treat solid tumors such as hepatocellular carcinoma (HCC) and colorectal cancer (CRC) respectively. A major obstacle in treating solid tumors with cell therapies is overcoming the immunosuppressive tumor microenvironment ...
First line cohort of the Phase 1b/2 DEDUCTIVE study demonstrates promising efficacy and tolerability of tivozanib plus durvalumab in first line HCC Two trials in progress posters presentations for the DEDUCTIVE HCC study and the recently initiated Phase 1b/2 IMMCO-1 study of tivozanib and atezolizumab in multiple immunologically cold tumors AVEO Oncology ...
For tivozanib, these milestones include initiation and continued enrollment of the Phase 3 TiNivo-2 clinical trial in advanced refractory RCC, and the presentation of data for the first-line cohort of the Phase 1b/2 DEDUCTIVE clinical trial in unresectable locally advanced or metastatic hepatocellular carcinoma (HCC) at American Society of Clinical Oncology ...
The prospective, single-center, open-label study will evaluate the safety and effectiveness of Eye90 microspheres™ in patients with unresectable hepatocellular carcinoma (HCC) or metastatic colorectal cancer (mCRC). Patients will receive a single Eye90 microspheres radioembolization treatment with follow-up visits for one year to assess safety, ...
This up to $4M over three-year award will be used to help ImCare Biotech pursue commercialization activities and support a pivotal clinical study for FDA clearance of Seravue®, a diagnostic testing product for Hepatocellular Carcinoma (HCC). This follows the promising results of a phase II clinical study, which demonstrated the high sensitivity and ...
Topline results from the ADP-A2AFP Phase 1 trial as of the April 5, 2021 data cutoff Efficacy Thirteen patients with advanced hepatocellular carcinoma (HCC) received ADP-A2AFP in Cohort 3 and expansion The best overall responses in Cohort 3 and expansion (per RECIST v1.1) included 1 complete response (reported in 2020), 6 stable disease and 4 progressive ...
In this study, the FlavourSpec® headspace analysis device showed that volatile organic compounds (VOCs) in urine could feasibly be used to identify hepatocellular carcinoma (HCC). These findings are good news for the possibility of early detection of a cancer that is often linked to end stages of a number of other chronic and fibrotic liver diseases and is ...
Seravue® is intended for use as an aid in the diagnosis of Hepatocellular Carcinoma (HCC), including early stage HCC, in patients with an elevated risk of developing HCC, in conjunction with ultrasound imaging or alone in cases where ultrasound is deemed inappropriate. ...
Seravue® is intended for use as an aid in the diagnosis of Hepatocellular Carcinoma (HCC), including early stage HCC, in patients with an elevated risk of developing HCC, in conjunction with ultrasound imaging or alone in cases where ultrasound is deemed inappropriate. ...
Funding of the remaining $4 million is due on completion of certain remaining milestones. Glycotest’s HCC Panel is a unique algorithm-driven biomarker panel that takes advantage of the Company’s patented fucosylated biomarker technology and is intended for surveillance of patients known to be at risk for hepatocellular carcinoma ...
PRLog - SFA Therapeutics, Inc. announced today that FDA has granted an official Orphan Drug Designation (ODD) to SFA001, the company's novel human-microbiome-based treatment for human hepatocellular carcinoma (HCC). "By granting an Orphan Drug Designation to SFA001, FDA has given a special status to treatment of the most prevalent form of liver cancer. ...